(Q37023469)

17 August 2017

1 reference

title

A systematic review of cost-utility analyses in HIV/AIDS: implications for public policy (English)

1 reference

17 August 2017

0 references

1 reference

Mark Holodniy

2

0 references

author name string

John Hornberger

1

1 reference

17 August 2017

Katherine Robertus

3

1 reference

17 August 2017

Michael Winnike

4

1 reference

17 August 2017

Erin Gibson

5

1 reference

17 August 2017

Eric Verhulst

6

1 reference

17 August 2017

publication date

1 November 2007

1 reference

17 August 2017

published in

Medical Decision Making

1 reference

17 August 2017

volume

27

1 reference

17 August 2017

issue

6

1 reference

17 August 2017

page(s)

789-821

1 reference

Recommendations of the Panel on Cost-effectiveness in Health and Medicine

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Evidence-based and value-based formulary guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

The Oregon experiment: the role of cost-benefit analysis in the allocation of Medicaid funds

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

An evaluation of Oregon's Medicaid rationing algorithms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Condom distribution: a cost-utility analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Value and cost-effectiveness of screening blood donors for antibody to hepatitis B core antigen as a way of detecting window-phase human immunodeficiency virus type 1 infections. The HIV Blood Donor Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

The cost-effectiveness of expanded testing for primary HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Rapid HIV versus enzyme-linked immunosorbent assay screening in a low-risk Mexican American population presenting in labor: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

The cost-effectiveness of human immunodeficiency virus screening in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

The cost-effectiveness of voluntary intrapartum rapid human immunodeficiency virus testing for women without adequate prenatal care

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Cost-effectiveness of cesarean section delivery to prevent mother-to-child transmission of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Cost-effectiveness of prevention referrals for high-risk HIV-negatives in San Francisco

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Cost-effectiveness of universal compared with voluntary screening for human immunodeficiency virus among pregnant women in Chicago.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Cost-effectiveness of an HIV risk reduction intervention for adults with severe mental illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Cost-effectiveness of a community-level HIV risk reduction intervention for women living in low-income housing developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Cost-effectiveness of syringe exchange as an HIV prevention strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Cost-effectiveness of a behavioral intervention for seropositive youth

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

The cost-effectiveness of voluntary counseling and testing of hospital inpatients for HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

The cost-effectiveness of elective Cesarean delivery for HIV-infected women with detectable HIV RNA during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Cost-effectiveness of interventions to reduce vertical HIV transmission from pregnant women who have not received prenatal care

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Cost-effectiveness of mandatory compared with voluntary screening for human immunodeficiency virus in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Screening surgeons for HIV infection. A cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Use of frozen semen to avoid human immunodeficiency virus type 1 transmission by donor insemination: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

The cost-effectiveness of HIV testing of physicians and dentists in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Cost-effectiveness of HIV-prevention skills training for men who have sex with men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

HIV-1 diversity in Romania

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Cost-effectiveness of a community-level HIV risk reduction intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Cost-threshold analyses of the National AIDS Demonstration Research HIV prevention interventions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Cost-effectiveness of HIV screening for incarcerated pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Cost effectiveness of human immunodeficiency virus postexposure prophylaxis for healthcare workers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

HIV screening of surgeons and dentists: a cost-effectiveness analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Cost-effectiveness of a brief video-based HIV intervention for African American and Latino sexually transmitted disease clinic clients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Economic evaluation of an HIV prevention intervention for gay and bisexual male adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Economic evaluation of an HIV prevention intervention for seropositive injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Cost-effectiveness of counseling and testing and partner notification: a decision analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Cost-effectiveness of HIV counseling and testing in US prisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Economic evaluation of Safer Choices: a school-based human immunodeficiency virus, other sexually transmitted diseases, and pregnancy prevention program

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

HIV transmission and the cost-effectiveness of methadone maintenance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Diagnostic yield and cost-effectiveness of endoscopy in chronic human immunodeficiency virus-related diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Economic analysis of initial HIV treatment. Efavirenz- versus indinavir-containing triple therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Validating literature-based models with direct clinical trial results: the cost-effectiveness of secondary prophylaxis for PCP in AIDS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

The cost-effectiveness of preventing AIDS-related opportunistic infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

The cost effectiveness of combination antiretroviral therapy for HIV disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

The impact of expected HIV transmission rates on the effectiveness and cost of ruling out HIV infection in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Cost effectiveness analysis of early zidovudine treatment of HIV infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Expanded screening for HIV in the United States--an analysis of cost-effectiveness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

The cost-effectiveness of expanded HIV counselling and testing in primary care settings: a first look.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Cost-effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: oral ganciclovir and CMV polymerase chain reaction testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

The cost-effectiveness of elective Cesarean delivery to prevent hepatitis C transmission in HIV-coinfected women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

The cost-effectiveness of fluconazole prophylaxis against primary systemic fungal infections in AIDS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Cost Effectiveness of Low-Dose Zidovudine Therapy for Asymptomatic Patients with Human Immunodeficiency Virus (HIV) Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

A comparison of the clinical and cost-effectiveness of 3 intervention strategies for AIDS wasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Routine human immunodeficiency virus testing: an economic evaluation of current guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Development and validation of a grading system for the quality of cost-effectiveness studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

A rational framework for decision making by the National Institute For Clinical Excellence (NICE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

What is the price of life and why doesn't it increase at the rate of inflation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Efficient management of diarrhea in the acquired immunodeficiency syndrome (AIDS). A medical decision analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

How HIV treatment advances affect the cost-effectiveness of prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

A therapeutic HIV vaccine: how good is good enough?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Modeling the Long-Term Outcomes and Costs of HIV Antiretroviral Therapy Using HIV RNA Levels: Application to a Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

Cost-Effectiveness of Earlier Initiation of Antiretroviral Therapy for Uninsured HIV-Infected Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07306112

21 January 2018

Identifiers

DOI

10.1177/0272989X07306112

1 reference

17 August 2017

1 reference